Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H23N5O2S2 |
Molecular Weight | 489.612 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=S(=O)(N1CC2=C(C=CC(=C2)C#N)N(CC3=CN=CN3)C[C@H]1CC4=CC=CC=C4)C5=CC=CS5
InChI
InChIKey=OLCWFLWEHWLBTO-HSZRJFAPSA-N
InChI=1S/C25H23N5O2S2/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22/h1-11,14,18,23H,12,15-17H2,(H,27,28)/t23-/m1/s1
Molecular Formula | C25H23N5O2S2 |
Molecular Weight | 489.612 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Bristol-Myers Squibb developed BMS-214662 as potent and selective farnesyl transferase inhibitor with potent antitumor activity. BMS-214662 participated in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers. However, further information is not available.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094108 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14741286 |
0.7 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17510207
Patients were treated every week as tolerated with i.v. paclitaxel (fixed dose, 80 mg/m(2)/wk) administered over 1 h followed by i.v. BMS-214662 (escalating doses, 80-245 mg/m(2)/wk) over 1 h starting 30 min after completion of paclitaxel.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:00:30 UTC 2023
by
admin
on
Fri Dec 15 18:00:30 UTC 2023
|
Record UNII |
L2U9GFD244
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2020
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
167655
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
PRIMARY | |||
|
L2U9GFD244
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
PRIMARY | |||
|
195987-41-8
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
PRIMARY | |||
|
C1856
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
PRIMARY | |||
|
DTXSID20173260
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
PRIMARY | |||
|
448545
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
PRIMARY | |||
|
DB12234
Created by
admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|